<a href="https://laohu8.com/S/AWH">Aspira Women's Health Inc.</a> Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices
Aspira Women's Health Inc. has announced a new collaboration with Dorsata to launch a clinical decision support module for adnexal masses. This partnership aims to modernize women's healthcare by integrating tech-enabled clinical tools to facilitate early detection and precision diagnostics. The new module is now available to over 700 women's health providers at more than 300 practice sites across 20 states, impacting the care of over 1.5 million patients annually. This initiative aligns with Aspira's strategy to expand the adoption of its Ova1Plus® and OvaWatch® products efficiently. Aspira CEO Mike Buhle expressed pride in this milestone, highlighting its significance in enhancing value for providers, patients, and the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women's Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040229) on June 17, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。